SEC Comment Letter 0000000000-24-006293 to NewcelX Ltd. (NCEL)
NewcelX Ltd.
Date: May 31, 2024 · CIK: 0001783036 · Accession: 0000000000-24-006293
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279806
Letter
United States securities and exchange commission logo May 31, 2024 Alexander Zwyer Chief Executive Officer NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland Re:NLS Pharmaceutics Ltd. Registration Statement on Form F-1 Filed May 30, 2024 File No. 333-279806 Dear Alexander Zwyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ron Ben-Bassat, Esq.
Show Raw Text
United States securities and exchange commission logo
May 31, 2024
Alexander Zwyer
Chief Executive Officer
NLS Pharmaceutics Ltd.
The Circle 6
8058 Zurich, Switzerland
Re:NLS Pharmaceutics Ltd.
Registration Statement on Form F-1
Filed May 30, 2024
File No. 333-279806
Dear Alexander Zwyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ron Ben-Bassat, Esq.